NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept and High Dose Interleukin-2 (HD IL-2) or HD IL-2 Alone for Inoperable Stage III or IV Melanoma

BACKGROUND: Interleukin-2 (IL2) is a growth factor for T and NK cells, promotes pro-inflammatory cytokines and can lead to durable responses in melanoma. VEGF promotes angiogenesis and modulates host innate and adaptive immunity. High VEGF levels were associated with nonresponse to IL2. Ziv- afliber...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Tarhini, Ahmad A., Frankel, Paul, Ruel, Christopher, Ernstoff, Marc S., Kuzel, Timothy M., Logan, Theodore F., Khushalani, Nikhil I., Tawbi, Hussein A., Margolin, Kim A., Awasthi, Sanjay, Butterfield, Lisa H., McDermott, David, Chen, Alice, Lara, Primo N., Kirkwood, John M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6504933/
https://ncbi.nlm.nih.gov/pubmed/30303516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31734
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados